Literature DB >> 24630700

The impact of multidrug resistance on outcomes in ventilator-associated pneumonia.

Rudy Tedja1, Amy Nowacki2, Thomas Fraser3, Cynthia Fatica4, Lori Griffiths4, Steven Gordon1, Carlos Isada1, David van Duin5.   

Abstract

Multidrug-resistant (MDR) organisms in ventilator-associated pneumonia were found in 49 of 107 patients and were associated with home antibiotics, pre-ventilator-associated pneumonia hospital stay, and health care exposure. Overall, MDR organisms were associated with increased mortality (P = .006). On multivariate analysis, MDR status was modulated by organism class. In nonfermenting gram-negative rods, no association between MDR and mortality was found, but, in all other organisms, MDR was associated with increased mortality risk (hazard ratio, 6.15; 95% confidence interval: 1.80-21.05, P = .004).
Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Hospital-acquired infections; Intensive care units; Multidrug-resistant organisms; Pseudomonas aeruginosa

Mesh：

Substances：

Year:  2014        PMID： 24630700     DOI： 10.1016/j.ajic.2013.12.009

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN： 0196-6553            Impact factor:   2.918


  12 in total

1.  Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Authors:  Kristina L Bailey; Andre C Kalil
Journal:  Curr Infect Dis Rep       Date:  2015-08       Impact factor: 3.725

2.  Timeline of health care-associated infections and pathogens after burn injuries.

Authors:  David van Duin; Paula D Strassle; Lauren M DiBiase; Anne M Lachiewicz; William A Rutala; Timothy Eitas; Robert Maile; Hajime Kanamori; David J Weber; Bruce A Cairns; Sonia Napravnik; Samuel W Jones
Journal:  Am J Infect Control       Date:  2016-10-11       Impact factor: 2.918

3.  Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections.

Authors:  C Hauck; E Cober; S S Richter; F Perez; R A Salata; R C Kalayjian; R R Watkins; N M Scalera; Y Doi; K S Kaye; S Evans; V G Fowler; R A Bonomo; D van Duin
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

4.  Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.

Authors:  Ignacio Martin-Loeches; Jean-François Timsit; Marin H Kollef; Richard G Wunderink; Nobuaki Shime; Martin Nováček; Ülo Kivistik; Álvaro Réa-Neto; Christopher J Bruno; Jennifer A Huntington; Gina Lin; Erin H Jensen; Mary Motyl; Brian Yu; Davis Gates; Joan R Butterton; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.758

Review 5.  Risk Factors of Multidrug-Resistant Bacteria in Lower Respiratory Tract Infections: A Systematic Review and Meta-Analysis.

Authors:  Gang Chen; Kailiang Xu; Fangyuan Sun; Yuxia Sun; Ziyuan Kong; Bangjiang Fang
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-06-30       Impact factor: 2.471

6.  A comparison of diagnostic algorithms and clinical parameters to diagnose ventilator-associated pneumonia: a prospective observational study.

Authors:  Farshid Rahimibashar; Andrew C Miller; Mojtaba H Yaghoobi; Amir Vahedian-Azimi
Journal:  BMC Pulm Med       Date:  2021-05-13       Impact factor: 3.317

7.  Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: A pilot study in pigs.

Authors:  Norman Zinne; Marcus Krueger; Doris Hoeltig; Burkhard Tuemmler; Erin C Boyle; Christian Biancosino; Klaus Hoeffler; Peter Braubach; Taufiek K Rajab; Anatol Ciubotaru; Judith Rohde; Karl-Heinz Waldmann; Axel Haverich
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

8.  Estimating the burden of antimicrobial resistance: a systematic literature review.

Authors:  Nichola R Naylor; Rifat Atun; Nina Zhu; Kavian Kulasabanathan; Sachin Silva; Anuja Chatterjee; Gwenan M Knight; Julie V Robotham
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-25       Impact factor: 4.887

9.  Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?

Authors:  Matteo Bassetti; Tobias Welte; Richard G Wunderink
Journal:  Crit Care       Date:  2016-01-29       Impact factor: 9.097

10.  Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307.

Authors:  S Wesley Long; Randall J Olsen; Todd N Eagar; Stephen B Beres; Picheng Zhao; James J Davis; Thomas Brettin; Fangfang Xia; James M Musser
Journal:  mBio       Date:  2017-05-16       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.